{
    "clinical_study": {
        "@rank": "144777", 
        "arm_group": {
            "arm_group_label": "IUGR"
        }, 
        "biospec_descr": {
            "textblock": "Blood test for H-p genotype"
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "Intra Uterine Growth Restriction is associated with increased oxidative stress. Haptoglobin\n      (Hp) is an abundant plasma glycoprotein produced in the liver. The function of Hp is as anti\n      oxidant agent, it binds free hemoglobin (Hb) released from red blood cells to decrease\n      oxidative tissue damage. There are 3 differenet genotype of haptoglobin Hp 1-1 Hp 1-2 and Hp\n      2-2 with different anti oxidant properties and different  prevalence ( Hp 1-1, Hp 1-2 and Hp\n      2-2approximately 16%, 48% and 36% respectively) . we hypotheise that IUGR will be more\n      common and severe in the Hp 2-2 genotype with the less anti oxidant properties."
        }, 
        "brief_title": "The Type of Hepatoglobin in IUGR", 
        "condition": "Haptoglobin Type", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Pregnancies complicated with IUGR -\n\n        Exclusion Criteria: NOT INTERESTED DO PARTICIPATE\n\n        -"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients adimitted with IUGR"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127385", 
            "org_study_id": "0001-14"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "number_of_groups": "1", 
        "official_title": "The Type of Hepatoglobin in IUGR", 
        "overall_official": {
            "affiliation": "HILLEL YAFFE MEDICAL CENTER- TECHNION", 
            "last_name": "RON BELOOSESKY, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "severity of iugr", 
            "measure": "type of haptoglobin", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127385"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hillel Yaffe Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hillel Yaffe Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}